September 20, 2022 02:32 PM EDT
Pharma
Law

Un­sealed doc­u­ments de­tail Bio­gen's fight against San­doz Tysabri biosim­i­lar

Nicole DeFeudis

Editor

San­doz is hop­ing to cel­e­brate its re­cent­ly an­nounced spin­off from No­var­tis with swift ap­provals for its Tysabri biosim­i­lar in both the US and Eu­rope …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times